Key result
Systemic thrombolysis yields no net benefit in submassive PE, offset by ~5.6-fold higher major bleeding.
Why the study?
In patients with submassive pulmonary embolism, systemic thrombolysis has not shown a clear benefit because hemodynamic improvements are offset by excess bleeding, and meta-analyses have yielded conflicting results on survival and post-PE syndrome prevention.
Does reperfusion therapy (systemic thrombolysis, half-dose thrombolysis, or catheter-directed therapy) improve clinical outcomes without prohibitive bleeding compared to anticoagulation alone in patients with submassive pulmonary embolism?
Does reperfusion therapy (systemic thrombolysis, half-dose thrombolysis, or catheter-directed therapy) improve clinical outcomes without prohibitive bleeding compared to anticoagulation alone in patients with submassive pulmonary embolism?
This review synthesizes the evidence showing that routine systemic thrombolysis is not justified in submassive PE due to bleeding risks, while highlighting emerging catheter-based, reduced-dose, and novel fibrinolytic strategies.
Answers are grounded in this paper and cite their sources.
Supports withholding routine systemic thrombolysis in submassive PE; leaves open evaluation of novel reperfusion strategies.
Submassive pulmonary embolism (PE) lies on a spectrum of disease severity between standard and high-risk disease. By definition, patients with submassive PE have a worse outcome than the majority of those with standard-risk PE, who are hemodynamically stable and lack imaging or laboratory features of cardiac dysfunction. Systemic thrombolytic therapy has been proven to reduce mortality in patients with high-risk disease; however, its use in submassive PE has not demonstrated a clear benefit, with haemodynamic improvements being offset by excess bleeding. Furthermore, meta-analyses have been confusing, with conflicting results on overall survival and net gain. As such, significant interest remains in optimising thrombolysis, with recent efforts in catheter-based delivery as well as upcoming studies on reduced systemic dosing. Recently, long-term cardiorespiratory limitations following submassive PE have been described, termed post-PE syndrome. Studies on the ability of thrombolytic therapy to prevent this condition also present conflicting evidence. In this review, we aim to clarify the current evidence with respect to submassive PE management, and also to highlight shortcomings in current definitions and prognostic factors. Additionally, we discuss novel therapies currently in preclinical and early clinical trials that may improve outcomes in patients with submassive PE.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2021) conducted a review in Submassive (intermediate-risk) pulmonary embolism. Systemic thrombolysis, catheter-directed thrombolysis, mechanical embolectomy, and novel antithrombotic/fibrinolytic therapies vs. Standard anticoagulation alone (low-molecular-weight heparin, unfractionated heparin, or direct oral anticoagulants) was evaluated. Routine systemic thrombolysis is not supported in submassive pulmonary embolism because reduced hemodynamic decompensation is offset by increased major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: